Setiptiline maleateSerotonin receptor antagonist CAS# 85650-57-3 |
2D Structure
- Laminin (925-933)
Catalog No.:BCC1015
CAS No.:110590-60-8
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 85650-57-3 | SDF | Download SDF |
PubChem ID | 5282470 | Appearance | Powder |
Formula | C23H23NO4 | M.Wt | 377.43 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 100 mg/mL (264.95 mM; Need ultrasonic) | ||
SMILES | CN1CCC2=C(C1)C3=CC=CC=C3CC4=CC=CC=C24.C(=CC(=O)O)C(=O)O | ||
Standard InChIKey | AVPIBVPBCWBXIU-BTJKTKAUSA-N | ||
Standard InChI | InChI=1S/C19H19N.C4H4O4/c1-20-11-10-18-16-8-4-2-6-14(16)12-15-7-3-5-9-17(15)19(18)13-20;5-3(6)1-2-4(7)8/h2-9H,10-13H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Setiptiline maleate Dilution Calculator
Setiptiline maleate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6495 mL | 13.2475 mL | 26.495 mL | 52.99 mL | 66.2374 mL |
5 mM | 0.5299 mL | 2.6495 mL | 5.299 mL | 10.598 mL | 13.2475 mL |
10 mM | 0.2649 mL | 1.3247 mL | 2.6495 mL | 5.299 mL | 6.6237 mL |
50 mM | 0.053 mL | 0.2649 mL | 0.5299 mL | 1.0598 mL | 1.3247 mL |
100 mM | 0.0265 mL | 0.1325 mL | 0.2649 mL | 0.5299 mL | 0.6624 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine. From Wikipedia.
- Asenapine
Catalog No.:BCC2476
CAS No.:85650-56-2
- Mirtazapine
Catalog No.:BCC4923
CAS No.:85650-52-8
- Laurycolactone B
Catalog No.:BCN3110
CAS No.:85643-77-2
- Laurycolactone A
Catalog No.:BCN3109
CAS No.:85643-76-1
- Curculigoside
Catalog No.:BCN4406
CAS No.:85643-19-2
- Boc-Ala-NH2
Catalog No.:BCC3046
CAS No.:85642-13-3
- WP1130
Catalog No.:BCC3686
CAS No.:856243-80-6
- Temozolomide
Catalog No.:BCC4386
CAS No.:85622-93-1
- (2-Aminoethyl)phosphinic acid
Catalog No.:BCN1761
CAS No.:85618-16-2
- Gynuramine
Catalog No.:BCN2085
CAS No.:85611-43-4
- Zaltidine
Catalog No.:BCC2068
CAS No.:85604-00-8
- Kurarinol
Catalog No.:BCN3447
CAS No.:855746-98-4
- Choline Fenofibrate
Catalog No.:BCC1478
CAS No.:856676-23-8
- CBiPES hydrochloride
Catalog No.:BCC7824
CAS No.:856702-40-4
- AM 114
Catalog No.:BCC3589
CAS No.:856849-35-9
- Tedizolid
Catalog No.:BCC1990
CAS No.:856866-72-3
- (-)-Blebbistatin
Catalog No.:BCC4375
CAS No.:856925-71-8
- alpha-Conidendrin
Catalog No.:BCN4407
CAS No.:85699-62-3
- (3S,3'R,8R,9R,9As)-8-methoxy-3'-methyl-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5'-oxolane]-2'-one
Catalog No.:BCC9250
CAS No.:85700-47-6
- Scopine HCl
Catalog No.:BCC4940
CAS No.:85700-55-6
- WP1066
Catalog No.:BCC2194
CAS No.:857064-38-1
- TMC353121
Catalog No.:BCC2004
CAS No.:857066-90-1
- PF 915275
Catalog No.:BCC7631
CAS No.:857290-04-1
- 3-Hydroxysarpagine
Catalog No.:BCN4566
CAS No.:857297-90-6
The effect of age on plasma level of setiptiline maleate in depressed patients.[Pubmed:7824756]
Prog Neuropsychopharmacol Biol Psychiatry. 1994 Oct;18(6):1015-26.
1. Setiptiline maleate (SPT) was administered orally to 45 subjects aged 22-86 years and steady state plasma levels were determined by mass fragment chromatography (GC-MF) to examine the effect of aging on those values. 2. There was a significant correlation between the plasma levels and daily dose. However, there was a wide interindividual variability. 3. Dose-corrected plasma level (DC-PL), or values corrected by dividing the plasma level by daily dose/body weight, was used as the systemic drug clearance parameter. 4. DC-PL was compared among 7 age groups of the subjects distributed in 10-year-intervals. DC-PL showed no difference among groups of subjects between the > 29 years bracket to the 70 years bracket, but showed significantly higher values in those in the > 80 bracket compared to all age groups and subjects in the < 79 bracket. 5. There was a significant correlation between the age of patients and DC-PL according to polynomial response curve analysis. Regression analysis yielded the equation y = -52.72 + 7.05 x -0.17 x2 + 0.01 x3 (n = 45, r = 0.49, p < 0.01).
Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia.[Pubmed:7516085]
Prog Neuropsychopharmacol Biol Psychiatry. 1994 Mar;18(2):339-46.
1. Setiptiline maleate was administered to schizophrenic patients with the object of improving their negative symptoms. 2. Moderate improvements were observed in 58% of the treated patients, thus usefulness of this drug was demonstrated. 3. There was no aggravation of symptoms, and side effects were minor. 4. Measurements of plasma monoamine metabolites showed a tendency of MHPG to decrease and a significant decrease in 5-HIAA, but no change in the level of HVA was observed, suggesting a relationship between the negative symptoms and noradrenaline and/or serotonin systems.